Title: Mounjaro and beyond: Dental considerations for GLP-1 receptor agonists
Abstract:
The rising use of Glucagon-Like Peptide-1 (GLP-1) receptor agonists commonly known as ‘skinny jabs’ or ‘weight loss injections’ - has brought these medications into more mainstream clinical use across the United Kingdom. Licensed for the management of Type 2 Diabetes and Obesity, their systemic benefits are well documented. However, their potential implications for oral health remain less explored. This piece highlights key clinical observations and practical considerations for general dental practitioners, including possible oral side effects and implications for treatment planning. As the use of GLP-1 receptor agonists continues to grow, dental teams must be adapt their knowledge and approach to reflect this evolving aspect of patient care.
